Merck & Company. which can be found using ticker (MRK) have now 24 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The range between the high target price and low target price is between 135 and 99 and has a mean target at $120.67. Now with the previous closing price of $114.13 this indicates there is a potential upside of 5.7%. Also worth taking note is the 50 day moving average now sits at $108.82 while the 200 day moving average is $100.66. The market cap for the company is $289,728m. Find out more information at: https://www.merck.com
The potential market cap would be $306,330m based on the market consensus.
Merck & Co.. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co.. was founded in 1891 and is headquartered in Rahway, New Jersey.
The company has a dividend yield of 2.56% with the ex dividend date set at 14-3-2023 (DMY).
Other points of data to note are a P/E ratio of 19.99, revenue per share of 23.41 and a 11.96% return on assets.
